A Randomized, Placebo Controlled, Double-blind, Dose Ranging Study to Evaluate the Safety and Tolerability of SCX-001 Cream in Healthy Volunteers With Induced Dermal Incisions

Trial Profile

A Randomized, Placebo Controlled, Double-blind, Dose Ranging Study to Evaluate the Safety and Tolerability of SCX-001 Cream in Healthy Volunteers With Induced Dermal Incisions

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Nefopam (Primary)
  • Indications Hypertrophic scars
  • Focus Adverse reactions
  • Sponsors ScarX Therapeutics
  • Most Recent Events

    • 27 Jun 2017 According to a ScarX therapeutics media release, company expects study results to be available in late 2017.
    • 27 Jun 2017 Status changed from recruiting to active, no longer recruiting, according to a ScarX therapeutics media release.
    • 18 Aug 2016 According to ScarX Therapeutics media release, the study results are expected to be available in Q3/2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top